| 1 |
33289516 | Bortezomib limits renal allograft interstitial fibrosis by inhibiting NF-κB/TNF-α/Akt/mTOR/P70S6K/Smurf2 pathway via IκBα protein stabilization. | 2021 Jan 15 |
3 |
| 2 |
33564319 | In Vitro Investigation of the Cytotoxic Activity of Emodin 35 Derivative on Multiple Myeloma Cell Lines. | 2021 |
1 |
| 3 |
33938943 | G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death. | 2021 May 11 |
1 |
| 4 |
32126150 | Inhibition of PLK4 might enhance the anti-tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway. | 2020 Apr |
1 |
| 5 |
33191863 | Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway. | 2020 Dec |
2 |
| 6 |
29997148 | Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway. | 2019 Jan |
1 |
| 7 |
31140729 | Bortezomib attenuates renal interstitial fibrosis in kidney transplantation via regulating the EMT induced by TNF-α-Smurf1-Akt-mTOR-P70S6K pathway. | 2019 Aug |
1 |
| 8 |
28696812 | A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma. | 2018 Mar |
1 |
| 9 |
28899456 | ClC5 Decreases the Sensitivity of Multiple Myeloma Cells to Bortezomib via Promoting Prosurvival Autophagy. | 2018 Apr 10 |
2 |
| 10 |
29057477 | The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs. | 2018 May |
2 |
| 11 |
29482577 | Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma. | 2018 Feb 27 |
1 |
| 12 |
29755672 | Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma. | 2018 Apr 17 |
1 |
| 13 |
29996117 | Blocking Mammalian Target of Rapamycin (mTOR) Alleviates Neuropathic Pain Induced by Chemotherapeutic Bortezomib. | 2018 |
5 |
| 14 |
28549771 | Calcineurin and mTOR Inhibitor-Free Post-Transplantation Cyclophosphamide and Bortezomib Combination for Graft-versus-Host Disease Prevention after Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I/II Study. | 2017 Oct |
1 |
| 15 |
25530422 | The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer. | 2015 Aug 1 |
2 |
| 16 |
26194835 | Effect of bortezomib on migration and invasion in cervical carcinoma HeLa cell. | 2015 Jun |
2 |
| 17 |
23916134 | Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation. | 2013 Dec |
1 |
| 18 |
26824026 | Cap dependent translation contributes to resistance of myeloma cells to bortezomib. | 2013 |
1 |
| 19 |
21909688 | Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. | 2012 Jan |
1 |
| 20 |
22313636 | Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor. | 2012 Apr |
1 |
| 21 |
22339676 | Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity. | 2012 Mar |
3 |
| 22 |
22560334 | The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. | 2012 Jul |
2 |
| 23 |
20100206 | Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity. | 2010 Apr |
1 |